Estradiol valerate/dienogest: A novel oral contraceptive;Valerato de estradiol/dienogest: un anticonceptivo nuevo

Annals of Pharmacotherapy

Volumn 45, Issue 10, 2011, Pages 1256-1261

  Whalen, Karen L ^a   Rose, Renee ^a  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

Author keywords

Contraception; Dienogest; Estradiol valerate; Natazia; Oral contraceptive; Qlaira

Indexed keywords

CYTOCHROME P450 3A4; DIENOGEST; ESTRADIOL VALERATE; ETHINYLESTRADIOL; FELBAMATE; GLUCOCORTICOID; LEVONORGESTREL; OXCARBAZEPINE; PHENYTOIN; RIFAMPICIN; TOPIRAMATE;

ACNE; CLINICAL TRIAL (TOPIC); DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG SAFETY; HEADACHE; HEART INFARCTION; HUMAN; IN VIVO STUDY; MASTALGIA; MENSTRUATION; METRORRHAGIA; NAUSEA AND VOMITING; OVARY CYST; PREGNANCY; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; UTERUS MYOMA; WEIGHT GAIN;

CLINICAL TRIALS AS TOPIC; CONTRACEPTIVES, ORAL; DRUG COMBINATIONS; DRUG COSTS; ESTRADIOL; FEMALE; HUMANS; NANDROLONE;

EID: 80054001740     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1Q216     Document Type: Review

References (22)

1. Burkman R, Bell C, Serfaty D. The evolution of combined oral contraception: improving the risk-to-benefit ratio. Contraception 2011;84:19-34. DOI 0.1016/j.contraception.2010.11.004.
2. Product information. Natazia (estradiol valerate/dienogest). Wayne, NJ: Bayer HealthCare Pharmaceuticals Inc., May 2010.
3. FDA approves new combination product oral contraceptive. www.fda. gov/NewsEvents/Newsroom/PressAnnouncements/ucm211176.htm (accessed 2011 Feb 1).
4. The electronic medicines compendium. Qlaira (estradiol valerate/ dienogest). www.medicines.org.uk/EMC/medicine/21700/SPC/Qlaira/ (accessed 2011 Jan 25).
5. Hoy SM, Scott LJ. Estradiol valerate/dienogest in oral contraception. Drugs 2009;69:1635-46.DOI 10.2165/11202820.
6. Endrikat J, Parke S, Trummer D, Schmidt W, Duijkers I, Klipping C. Ovulation inhibition with four variations of a four-phasic estradiol valerate/ dienogest combined oral contraceptive: results of two prospective, randomized, open-label studies. Contraception 2008;78:218-25.DOI 10.1016/j.contraception.2008.05.004
7. Wellington K, Perry CM. Estradiol valerate/dienogest. Drugs 2002;62: 491-504; discussion 505-6.
8. Zeun S, Lu M, Uddin A, Zeiler B, Morrison D, Blode H. Pharmacokinetics of an oral contraceptive containing oestradiol valerate and dienogest. Eur J Contracept Reprod Health Care 2009;14:221-32. DOI 10.1080/13625180902850039
9. Mashchak CA, Lobo RA, Dozono-Takano R, et al. Comparison of pharmacodynamic properties of various estrogen formulations. Am J Obstet Gynecol 1982;144:511-8.
10. Wiegratz I, Lee JH, Kutschera E, Winkler UH, Kuhl H. Effect of four oral contraceptives on hemostatic parameters. Contraception 2004;70:97-106.
11. Lindberg UB, Crona N, Stigendal L, Teger-Nilsson AC, Silfverstolpe G. A comparison between effects of estradiol valerate and low dose ethinylestradiol on haemostasis parameters. Thromb Haemost 1989;61: 65-9.
12. Levin ER, Hammes SR. Estrogens and progestins. In: Brunton LL, Chabner BA, Knollmann BC, eds. Goodman & Gilman's the pharmacological basis of therapeutics. 12th ed. http://www.accesspharmacy.com. lp.hscl.ufl.edu/content.aspx?aID=16673417 (accessed 2011 Feb 23).
13. Oettel M, Breitbarth H, Elger W, Gräser T, Hübler D, Kaufmann G, et al. The pharmacological profile of dienogest. Eur J Contracept Reprod Health Care 1999;4(suppl 1):2-13.
14. Guida M, Bifulco G, Di Spiezio Sardo A, Scala M, Fernandez LM, Nappi C. Review of the safety, efficacy and patient acceptability of the combined dienogest/estradiol valerate contraceptive pill. Int J Women's Health 2010;2:279-90. DOI 10.2147/IJWH.S6954
15. Hoogland HJ, Skouby SO. Ultrasound evaluation of ovarian activity under oral contraceptives. Contraception 1993;47:583-90.
16. Ahrendt H-J, Makalova D, Parke S, Mellinger U, Mansour D. Bleeding pattern and cycle control with an estradiol-based oral contraceptive: a seven-cycle, randomized comparative trial of estradiol valerate/dienogest and ethinylestradiol/levonorgestrel. Contraception 2009;80:436-44. DOI 10.1016/j.contraception.2009.03.018
17. Jensen JT, Parke S, Mellinger U, Machlitt A, Fraser IS. Effective treatment of heavy menstrual bleeding with estradiol valerate and dienogest: a randomized controlled trial. Obstet Gynecol 2011;117:777-87. DOI 10.1097/AOG.0b013e3182118ac3
18. Palacios S, Wildt L, Parke S, Machlitt A, Römer T, Bitzer J. Efficacy and safety of a novel oral contraceptive based on oestradiol (oestradiol valerate/ dienogest): a phase III trial. Eur J Obstet Gynecol Reprod Biology 2010;149:57-62. DOI 10.1016/j.ejogrb.2009.11.001
19. Parke S, Nahum GG, Mellinger U, Junge W. Metabolic effects of a new four-phasic oral contraceptive containing estradiol valerate and dienogest (abstract). Obstet Gynecol 2008;111(suppl 4):12-3S.
20. Klipping C, Duijkers I, Parke S, Mellinger U, Serrani M, Junge W. Hemostatic effects of a novel estradiol-based oral contraceptive: an openlabel, randomized, crossover study of estradiol valerate/dienogest versus ethinylestradiol/levonorgestrel. Drugs R D 2011;11:159-70.
21. International Active Surveillance Study-Safety of Contraceptives: Role of Estrogens (INAS-SCORE). http://clinicaltrials.gov/ct2/show/NCT01009684 (accessed 2011 Jul 26)
22. Cardinal Health. www.cardinal.com (accessed 2011 Jul 28).